Pfizer stock: Pfizer licenses Starna's early CAR-T programs
Published on 11/20/2026 at 17:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer expands its pipeline
- Pfizer secured rights outside Greater China to Starna's in vivo CAR-T programs for autoimmune diseases.
- Starna will receive upfront and milestone payments, while Pfizer leads development in its territories.
- The programs remain at a pre-IND stage, leaving clinical progress as the next major test.
Pfizer announced on Wednesday, November 18, that it had entered an exclusive licensing agreement with Starna Therapeutics covering three pre-IND in vivo CAR-T programs for autoimmune diseases. The deal broadens Pfizer's inflammation and immunology pipeline and gives the company development rights outside Greater China.
Rights extend beyond autoimmune research
Under the agreement, Pfizer can develop, manufacture and commercialize the three programs outside Greater China. The company also received rights to use Starna's in vivo CAR-T technology in inflammation, immunology and oncology, along with options covering compounds from a separate research collaboration and a possible expansion into Greater China.
The Pfizer investor release said Starna will receive an upfront payment of 330 million US dollars and may receive up to 2.3 billion US dollars in development and commercial milestones, plus royalties on approved-product sales. Pfizer will lead clinical development outside Greater China and plans to manufacture finished drug product for initial trials at its US facilities.
Clinical progress remains ahead
The three programs are still before human trials. In vivo CAR-T is designed to reprogram immune cells directly inside the body, while conventional CAR-T typically requires cells to be collected, modified outside the body and reinfused. For investors, the value of the license therefore depends on whether the programs advance through clinical development and later regulatory review.
Pfizer Inc.
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Home exchange: NYSE
- Announcement date: November 18, 2026
US market context is available in Current market reports.
